Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

According to data from an analysis of 80 patients with HER2-positive metastatic breast cancer who received long-term trastuzumab, using endocrine therapy with trastuzumab (p = 0.04), menopausal status (p = 0.03), and the number of metastatic sites (p = 0.01) were found to be statistically significant factors for complete response.